Effects of Spirulina supplementation in patients with ulcerative colitis: a double-blind, placebo-controlled randomized trial

Table 4 Descriptive statistics of variables by group and time-point

Variable	Group	Post - Pre	P-value*
SOD (U/mL)	SP	0.24 ± 5.45	0.795
SOD (U/mL)	PL	− 0.35 ± 6.62	0.752
TAC (nmol/mL)	SP	19.18 ± 65.83	0.089
TAC (nmol/mL)	PL	−11.33 ± 61.92	0.273
Pentraxin 3 (ng/mL)	SP	−2.03 ± 7.12	0.096
Pentraxin 3 (ng/mL)	PL	−0.23 ± 5.60	0.799
MDA (nmol/mL)	SP	−7.42 ± 16.45	0.010
MDA (nmol/mL)	PL	−2.11 ± 17.61	0.471
ESR (mm/h)	SP	−4.61 ± 19.01	0.155
ESR (mm/h)	PL	−0.86 ± 9.38	0.578
SCCAI score	SP	−0.42 ± 3.56	0.487
SCCAI score	PL	−0.24 ± 3.76	0.696
SIBDQ score	SP	6.69 ± 7.70	< 0.001
SIBDQ score	PL	2.89 ± 6.67	0.012

TAC total antioxidant capacity, MDA Malondialdehyde, SOD Superoxide dismutase, ESR Erythrocyte sedimentation rate, SCCAI Simple Clinical Colitis Activity Index, SP Spirulina, PL Placebo
*The p-value of paired t-test

ISSN: 2662-7671